## Supplementary Information

## Anticancer Activity of Pt-Selenolate Metallacycles

M. K. Pal ${ }^{\text {a }}$, A. G. Majumdar ${ }^{\text {b }}$, K. V. Vivekananda ${ }^{\text {a }}$, A. P. Wadawale ${ }^{\text {a }}$, M. Subramanian ${ }^{\text {b }}$, N. Bhuvanesh ${ }^{\text {c }}$ and S. Dey ${ }^{\text {a,d,* }}$<br>${ }^{a}$ Chemistry Division, Bhabha Atomic Research Centre, Mumbai 400 085, India<br>${ }^{\text {b }}$ Bio-Organic Division, Bhabha Atomic Research Centre, Mumbai 400 085, India<br>${ }^{\text {c }}$ Department of Chemistry, Texas A\&M University, PO Box 30012, College Station, Texas 77842-3012, USA<br>${ }^{\text {d }}$ Homi Bhabha National Institute, Training School Complex, Mumbai-400094, India * E-mail: dsandip@barc.gov.in (S. Dey); Tel: +91-22-2559-2589

## Table of Contents

| Sr No | Contents | Page <br> no. |
| :---: | :---: | :---: |
| 1 | Materials and methods | 2 |
| 2 | X-ray Crystallography | 4 |
| 3 | References | 5 |
| 4 | Experimental details of biological evaluation | 6-9 |
| 5 | Crystallographic and structure refinement data | 10-12 |
| 6 | Calculated and experimental peaks of the fragmented ions of 7,9 and $\mathbf{1 0}$ | 13-15 |
| 7 | ${ }^{1} \mathrm{H},{ }^{31} \mathrm{P}$ and ${ }^{195} \mathrm{Pt}$ NMR spectra of compounds 1-2 in $\mathrm{CDCl}_{3}$ | 16-20 |
| 8 | ${ }^{1} \mathrm{H},{ }^{31} \mathrm{P},{ }^{77} \mathrm{Se}$ and ${ }^{195} \mathrm{Pt}$ NMR spectra of compounds $\mathbf{6 , 7 , 9}$ and $\mathbf{1 0}$ in $\mathrm{CD}_{2} \mathrm{Cl}_{2}$ | 21-36 |
| 9 | ${ }^{1} \mathrm{H}$ and ${ }^{31} \mathrm{P}$ NMR spectra of compound 10 in DMSO-d ${ }_{6}$ | 37-38 |
| 10 | Structural drawing of $\left[\mathrm{Pt}_{2}\left(\mathrm{PEt}_{3}\right)_{4}\left(\mathrm{~S}\left(\mathrm{C}_{12} \mathrm{H}_{8}\right) \mathrm{S}\right)\right]_{2}(\mathrm{OTf})_{4}(\mathbf{1 1})$ | 39 |
| 11 | ORTEP diagram of complex 12D and 13D | 40-41 |
| 12 | ESI mass-spectrum of complex 9 and 10 | 42-43 |
| 13 | ORTEP diagram of complex 1 and 9T | 44-45 |
| 14 | ${ }^{1} \mathrm{H}$ NMR spectra of complex $\left[\mathrm{Pt}\left(\mathrm{PEt}_{3}\right)_{2}(4-\mathrm{Sepy})\right]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}} \mathbf{1 0}$ in the mixture of cell culture medium and DMSO- $\mathrm{d}_{6}(1: 4, \mathrm{v} / \mathrm{v})$ at different time interval | 46 |
| 15 | UV-Vis spectra of $\left[\mathrm{Pt}_{( }\left(\mathrm{PEt}_{3}\right)_{2}(4-\mathrm{Sepy})\right]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(\mathbf{1 0})$ in mixture of cell culture medium and DMSO ( $1: 4, \mathrm{v} / \mathrm{v}$ ) overtime scale | 47 |
| 16 | Dose response curve by MTT and clonogenic assay | 48-49 |


| 17 | Histograms representing Sub G1 analysis of MCF7 cells treated with the <br> different compounds | 50 |
| :--- | :--- | :--- |
| 18 | Cell cycle analysis of MCF7 cells treated with indicated concentrations of <br> the different compounds | 51 |

## Materials and methods

All experiments were carried out under a nitrogen atmosphere by using standard Schlenk technique. Solvents used in the reactions were degassed with nitrogen and distilled using standard procedures. The 4,4'-dipyridyldisulfide (4,4-py2 $\mathrm{S}_{2}$ ) was used as purchased from commercial sources without further purification. The ligand 4,4'-dipyridyldiselenide (4,4$\mathrm{py}_{2} \mathrm{Se}_{2}{ }^{1}$, the precursor complexes $\left[\mathrm{Pt}\left(\mathrm{PEt}_{3}\right)_{2}(\mathrm{OTf})_{2}\right],\left[\mathrm{Pt}(\mathrm{dppe})(\mathrm{OTf})_{2}\right]$ and $\left[\mathrm{Pt}(\mathrm{dppf})(\mathrm{OTf})_{2}\right]^{2,3}$ and the selenolate complexes $\left[\mathrm{PdCl}\left(\mathrm{PPh}_{3}\right)_{2}(4-\mathrm{Sepy})\right]$ (3), $\left[\mathrm{PtCl}\left(\mathrm{PEt}_{3}\right)_{2}(4-\mathrm{Sepy})\right]$ (4), $[\mathrm{Pd}(\mathrm{dppe})(4-\mathrm{Sepy})]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}} \quad(5), \quad[\mathrm{Pd}(\mathrm{dppf})(4-\mathrm{Sepy})]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}} \quad(8)$ and dithiolate complex $\left[\mathrm{Pt}_{2}\left(\mathrm{PEt}_{3}\right)_{4}\left(\mathrm{SC}_{12} \mathrm{H}_{8} \mathrm{~S}\right)\right]_{2}(\mathrm{OTf})_{4}(\mathbf{1 1})$ were prepared by literature methods. ${ }^{4,5}$ Melting points were determined in capillary tubes and are uncorrected. Elemental analyses were carried out on a Thermo Fischer Flash EA1112 CHNS analyzer. UV-vis absorption spectra were recorded in dichloromethane using JASCO V-630 spectrophotometer. ${ }^{1} \mathrm{H}$ NMR spectra were recorded on a Bruker and Varian NMR spectrometers operating at 300, 400 and 500 MHz , chemical shifts are relative to internal dichloromethane $-d_{2}$ and chloroform- $d_{1}$ peak ( $\delta 5.30$ and $\delta 7.26$ ). The chemical shifts $(\delta)$ were reported in parts per million (ppm). The coupling constants $(J)$ are quoted in Hertz (Hz). Proton splitting patterns are described as $s$ (singlet), d (doublet), t (triplet), and $m$ (multiplet). For ${ }^{31} \mathrm{P}\left\{{ }^{1} \mathrm{H}\right\}$ NMR spectra were recorded on NMR spectrometer operating at 121.46 and $243.17 \mathrm{MHz},{ }^{19} \mathrm{~F}\left\{{ }^{1} \mathrm{H}\right\},{ }^{77} \mathrm{Se}\left\{{ }^{1} \mathrm{H}\right\}$ and ${ }^{195} \mathrm{Pt}\left\{{ }^{1} \mathrm{H}\right\}$ NMR spectra were recorded on a Bruker NMR spectrometer operating at 282.38 , 57.2 and 64.5 MHz respectively. Mass spectra were recorded on a maXis Impact (Bruker) mass spectrometer.

## Synthesis of Complexes

## $\left[\mathbf{P t}(\mathrm{dppf})(4-\mathrm{Spy})_{2}\right](\mathbf{1})$

To a methanolic solution ( 10 ml ) of $\mathrm{Na}(4-\mathrm{Spy})$ (freshly prepared from 4,4'-py $\mathrm{S}_{2}$ ( 19.4 mg , $0.088 \mathrm{mmol})$ and $\mathrm{NaBH}_{4}(8.0 \mathrm{mg}, 0.211 \mathrm{mmol})$ ), a dichloromethane solution ( 10 ml ) of $\left[\mathrm{Pt}(\mathrm{dppf}) \mathrm{Cl}_{2}\right](72.2 \mathrm{mg}, 0.088 \mathrm{mmol})$ was added and stirred for 3 h . Solvents were removed using vacuuo to get yellow solid, which was washed with hexane and diethyl ether. The residue was recrystallized from dichloromethane-hexane mixture to afford yellow crystals of the title compound ( $72.3 \mathrm{mg}, 85 \%$ ), $\mathrm{mp}>200{ }^{\circ} \mathrm{C}$. Anal. Calcd for $\mathrm{C}_{44} \mathrm{H}_{36} \mathrm{~N}_{2} \mathrm{P}_{2} \mathrm{~S}_{2} \mathrm{PtFe}$ : C, 54.49; H, 3.74; N, 2.89; Found C, 54.81 ; H, 3.94; N, 2.61\%. UV/vis (dichloromethane): $\lambda_{\max }\left(\varepsilon\right.$ in $\mathrm{M}^{-1}$ $\mathrm{cm}^{-1}$ ) 294 (sh, 7257) nm. ${ }^{1} \mathrm{H}$ NMR ( $300 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ) $\delta: 4.20\left(\mathrm{~s}, 4 \mathrm{H}, \mathrm{H}_{\beta}\right.$-ferr), $4.37(\mathrm{~s}, 4 \mathrm{H}$, $\mathrm{H}_{\alpha}$-ferr), $7.04\left(\mathrm{~d},{ }^{3} J_{\mathrm{H}, \mathrm{H}}=5.1 \mathrm{~Hz}, 4 \mathrm{H}, \mathrm{H}_{\beta}-\mathrm{Py}\right), 7.32\left(\mathrm{t},{ }^{3} J_{\mathrm{H}, \mathrm{H}}=6.9 \mathrm{~Hz}, 8 \mathrm{H}, m-\mathrm{H}\right.$ of Ph$), 7.41(\mathrm{~d}$, ${ }^{3} J_{\mathrm{H}, \mathrm{H}}=7.2 \mathrm{~Hz}, 4 \mathrm{H}, p-\mathrm{H}$ of Ph$), 7.76\left(\mathrm{t},{ }^{3} J_{\mathrm{H}, \mathrm{H}}=8.1 \mathrm{~Hz}, 8 \mathrm{H}, o-\mathrm{H}\right.$ of Ph$), 7.85\left(\mathrm{~d},{ }^{3} J_{\mathrm{H}, \mathrm{H}}=5.1 \mathrm{~Hz}\right.$, 4H, $\left.\mathrm{H}_{\alpha}-\mathrm{Py}\right) .{ }^{31} \mathrm{P}\left\{{ }^{1} \mathrm{H}\right\}$ NMR ( $121.5 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ) $\delta: 17.6\left(\mathrm{~s},{ }^{1} J_{\mathrm{P}-\mathrm{Pt}}=3034 \mathrm{~Hz}\right) \mathrm{ppm} .{ }^{195} \mathrm{P}\left\{{ }^{1} \mathrm{H}\right\}$ NMR ( $64.5 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ) $\delta:-4685\left(\mathrm{t},{ }^{1} J_{\mathrm{P}-\mathrm{Pt}}=3033 \mathrm{~Hz}\right) \mathrm{ppm}$.

## $\left[\mathbf{P t}(\mathrm{dppf})(4-\mathrm{Sepy})_{2}\right](\mathbf{2})$

Prepared in a similar manner to that for $\mathbf{1}$, using $4,4^{\prime}-\mathrm{py}_{2} \mathrm{Se}_{2}(34.0 \mathrm{mg}, 0.108 \mathrm{mmol}), \mathrm{NaBH}_{4}$ $(9.0 \mathrm{mg}, 0.238 \mathrm{mmol})$ and $\left[\mathrm{Pt}(\mathrm{dppf}) \mathrm{Cl}_{2}\right](88.8 \mathrm{mg}, 0.108 \mathrm{mmol})$ and recrystallized from dichloromethane-hexane mixture to afford orange crystals of the title compound ( 89.4 mg , $78 \%), \mathrm{mp}>200^{\circ} \mathrm{C}$. Anal. Calcd for $\mathrm{C}_{44} \mathrm{H}_{36} \mathrm{~N}_{2} \mathrm{P}_{2} \mathrm{Se} \mathrm{Se}_{2} \mathrm{PtFe}$ C, $49.69 ; \mathrm{H}, 3.41 ; \mathrm{N}, 2.63$; Found C, 49.44; H, 3.58; N, 2.26\%. UV/vis (dichloromethane): $\lambda_{\max }\left(\varepsilon\right.$ in $\left.\mathrm{M}^{-1} \mathrm{~cm}^{-1}\right) 294(\mathrm{sh}, 4894) \mathrm{nm}$. ${ }^{1} \mathrm{H}$ NMR ( $600 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ) $\delta: 4.19\left(\mathrm{~s}, 4 \mathrm{H}, \mathrm{H}_{\beta}\right.$-ferr), $4.34\left(\mathrm{~s}, 4 \mathrm{H}, \mathrm{H}_{\alpha}\right.$-ferr), $7.18\left(\mathrm{~d},{ }^{3} J_{\mathrm{H}, \mathrm{H}}=5.4\right.$ $\left.\mathrm{Hz}, 4 \mathrm{H}, \mathrm{H}_{\beta}-\mathrm{Py}\right), 7.35\left(\mathrm{t},{ }^{3} J_{\mathrm{H}, \mathrm{H}}=7.5 \mathrm{~Hz}, 8 \mathrm{H}, m-\mathrm{H}\right.$ of Ph$), 7.44\left(\mathrm{t},{ }^{3} J_{\mathrm{H}, \mathrm{H}}=7.5 \mathrm{~Hz}, 4 \mathrm{H}, p-\mathrm{H}\right.$ of Ph$)$, $7.81\left(\mathrm{t},{ }^{3} J_{\mathrm{H}, \mathrm{H}}=9.0 \mathrm{~Hz}, 8 \mathrm{H}, o-\mathrm{H}\right.$ of Ph), $7.85\left(\mathrm{~d},{ }^{3} J_{\mathrm{H}, \mathrm{H}}=5.4 \mathrm{~Hz}, 4 \mathrm{H}, \mathrm{H}_{\alpha}-\mathrm{Py}\right) .{ }^{31} \mathrm{P}\left\{{ }^{1} \mathrm{H}\right\} \operatorname{NMR}(243$ $\left.\mathrm{MHz}, \mathrm{CDCl}_{3}\right) \delta: 12.2\left({ }^{1} J_{\mathrm{P}-\mathrm{Pt}}=3083 \mathrm{~Hz},{ }^{1} J_{\mathrm{P}-\mathrm{Se}}=51 \mathrm{~Hz}\right) \mathrm{ppm}$.

## X-ray Crystallography

A Rigaku-Oxford make XtaLAB Synergy, Dualflex X-ray diffractometer was employed for crystal screening, unit cell determination, and data collection. The goniometer was controlled using the APEX3 software suite. ${ }^{6}$ The X-ray radiation employed was generated from a Mo Xray tube $\mathrm{K} \alpha(\lambda=0.71073 \AA)$. Integrated intensity information for each reflection was obtained by reduction of the data frames with the program APEX3. ${ }^{6}$ The integration method employed a three-dimensional profiling algorithm and all data were corrected for Lorentz and polarization factors, as well as for crystal decay effects. Finally, the data was merged and scaled to produce a suitable data set. The absorption correction program SADABS $^{7}$ was employed to correct the data for absorption effects. Systematic reflection conditions and statistical tests of the data suggested the space group Cc. A solution was obtained readily using XT/XS in APEX3. ${ }^{6,8}$ Hydrogen atoms were placed in idealized positions and were set riding on the respective parent atoms. All non-hydrogen atoms were refined with anisotropic thermal parameters. The structure was refined (weighted least squares refinement on $F^{2}$ ) to convergence. ${ }^{8,9}$ Olex2 was employed for the final data presentation and structure plots. ${ }^{9}$

## \#Calculations for masked entities

Compd. 1 (218066)
A solvent mask was calculated using PLATON SQUEEZE and 115 electrons were found in a volume of $310 \AA 3$ in 1 void per unit cell. This is consistent with the presence of $1\left(\left(\mathrm{CHCl}_{3}\right)\right.$ ] accounting for 58 electrons per Formula Unit which account for 116 electrons per unit cell Moiety formula: $\mathrm{C}_{44} \mathrm{H}_{36} \mathrm{Fe} \mathrm{N}_{2} \mathrm{P}_{2} \mathrm{Pt} \mathrm{S}_{2}$, C H Cl ${ }_{3}$ Molecular formula: $\mathrm{C}_{45} \mathrm{H}_{37} \mathrm{Cl}_{3} \mathrm{FeN}_{2} \mathrm{P}_{2} \mathrm{PtS}_{2}$

A solvent mask was calculated and 1316 electrons were found in a volume of $5155 \AA 3$ in 1 void per unit cell. This is consistent with the presence of $2\left[\mathrm{CF}_{3} \mathrm{SO}_{3} \mathrm{H}\right]$ accounting for 148 and $3\left(\mathrm{CHCl}_{3}\right]$ accounting for 174 electrons per Formula Unit which account for 1288 electrons per unit cell

Moiety formula: $\mathrm{C}_{156} \mathrm{H}_{128} \mathrm{Fe}_{4} \mathrm{~N}_{4} \mathrm{P}_{8} \mathrm{Pt}_{4} \mathrm{~S}_{4}, 4\left(\mathrm{C} \mathrm{F}_{3} \mathrm{O}_{3} \mathrm{~S}\right)$. [2( $\left.\left.\mathrm{C} \mathrm{F}_{3} \mathrm{O}_{3} \mathrm{~S} \mathrm{H}\right), 3\left(\mathrm{C} \mathrm{H} \mathrm{Cl}_{3}\right)\right]$
Molecular formula: $\mathrm{C}_{165} \mathrm{H}_{133} \mathrm{Cl}_{9} \mathrm{~F}_{18} \mathrm{Fe}_{4} \mathrm{~N}_{4} \mathrm{O}_{18} \mathrm{P}_{8} \mathrm{Pt}_{4} \mathrm{~S}_{10}$

## Compd. 9T (2180270)

A solvent mask was calculated and 837 electrons were found in a volume of $3278 \AA 3$ in 1 void per unit cell. This is consistent with the presence of $2\left[\mathrm{CF}_{3} \mathrm{SO}_{3} \mathrm{H}\right]$ accounting for 148 and 5(CHCl3] accounting for 58 per Formula Unit which account for 824 electrons per unit cell Moiety formula: $\mathrm{C}_{156} \mathrm{H}_{128} \mathrm{Fe}_{4} \mathrm{~N}_{4} \mathrm{P}_{8} \mathrm{Pt}_{4} \mathrm{Se}_{4}, 4\left(\mathrm{C} \mathrm{F}_{3} \mathrm{O}_{3} \mathrm{~S}\right), 2\left(\mathrm{C} \mathrm{F}_{3} \mathrm{O}_{3} \mathrm{~S} \mathrm{H}\right), 5\left(\mathrm{CHCl}_{3}\right)$ Molecular formula: $\mathrm{C}_{167} \mathrm{H}_{135} \mathrm{Cl}_{15} \mathrm{~F}_{18} \mathrm{Fe}_{4} \mathrm{~N}_{4} \mathrm{O}_{18} \mathrm{P}_{8} \mathrm{Pt}_{4} \mathrm{~S}_{6} \mathrm{Se}_{4}$

## References

1. B. Boduszek and R. Gancarz, J. Prakt. Chem., 1996, 338, 186-189.
2. P. A. Mane, S. Dey, A. K. Pathak, M. Kumar, N. Bhuvanesh, Inorg. Chem., 2019, 58, 2965-2978.
3. P. J. Stang, B. Olenyuk, J. Fan and A. M. Arif, Organometallics, 1996, 15, 904-908.
4. K. V. Vivekananda, S. Dey, A. Wadawale, N. Bhuvanesh, V. K. Jain, Dalton Trans., 2013, 42, 14158.
5. P. A. Mane, A. K. Pathak, N. Bhuvanesh and S. Dey, Inorg. Chem. Front., 2021, 8, 3815-3829.
6. APEX3 "Program for Data Collection on Area Detectors" BRUKER AXS Inc., 5465 East Cheryl Parkway, Madison, WI 53711-5373 USA.
7. G. M. Sheldrick, SADABS, "Program for Absorption Correction of Area Detector Frames", BRUKER AXS Inc., 5465 East Cheryl Parkway, Madison, WI 53711-5373 USA.
8. (a) G. M. Sheldrick, Acta Cryst., 2008, A64, 112-122. (b) G. M. Sheldrick, Acta Cryst., 2015, A71, 3-8. (c) G. M. Sheldrick, Acta Cryst., 2015, C71, 3-8. XT, XS, BRUKER AXS Inc., 5465 East Cheryl Parkway, Madison, WI 53711-5373 USA.
9. O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard and H. Puschmann, "OLEX2: A Complete Structure Solution, Refinement and Analysis Program", J. Appl. Cryst., 2009, 42, 339-341.

## CT-DNA Interaction Studies

The stock solution of CT-DNA was prepared by dissolving requisite amount of DNA in TrisHCl buffer solution ( $10 \mathrm{mM} ; \mathrm{pH}=7.5$ ). The ratio of $\mathrm{UV}-V$ is absorbance at 260 nm and 280 nm of the solution (calcd. 1.85) indicates that CT-DNA sample doesn't have any protein contamination. The concentration of the DNA stock solution was measured by considering the molar extinction coefficient of the CT-DNA at 260 nm to be $6600 \mathrm{M}^{-1} \mathrm{~cm}^{-1}$. The stock solution of the complex was prepared in DMSO-buffer mixture ( $\mathrm{v} / \mathrm{v}=1: 1000$ ). All the data were recorded at room temperature. The absorption study was performed by maintaining the concentration of the complex constant and varying DNA concentration. The absorption spectra were recorded for $[\mathrm{Pt}(\mathrm{dppf})(4-\mathrm{Spy})]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(7)(22 \mu \mathrm{M})$ followed by gradual addition of the CT-DNA solution (for range of $0-4.32 \mu \mathrm{M}$ ). The spectra were recorded after equilibration for 5 min , allowing the complexes to bind to the CT-DNA.

## Biological evaluation

Cell viability assay. $\mathrm{IC}_{50}$ values of the different compounds against MCF-7 cells were determined using the MTT assay. Briefly, $7.5 \times 10^{3}$ cells were seeded in 96 well plates; 16 h
post seeding, cells were treated with different concentrations of the compounds (in triplicates) and incubated for 48 h . For determining cellular viability post treatment, the culture medium was replaced with medium containing $0.5 \mathrm{mg} / \mathrm{mL}$ of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) reagent. Cells were incubated for 4 h , followed by dissolution of the formazan crystals in DMSO. Absorbance was recorded at 570 nm in a microplate reader (Omega series, BMG Labtech). Percentage viability at each concentration of compound was calculated on the basis of the absorbance of the respective untreated sample.

Clonogenic assay. Colony formation (clonogenic) assay was used to evaluate the effect of the compounds on cellular viability of MCF-7 cells. Briefly, 500 cells were seeded in a 6 well plates, followed by 16 h incubation to facilitate cellular attachment. Post attachment, cells were treated with different concentrations of the compounds, and incubated for 12 days. Colonies were then fixed with $3.5 \%$ paraformaldehyde, followed by staining with a $0.5 \%$ crystal violet solution. Post staining, colonies were counted under a light microscope. Colonies containing more than 30 cells were considered for calculations. Percentage survival was calculated based on normalization with the corresponding untreated samples.

Cell cycle analysis. The effect of different compounds on the cell cycle distribution of MCF7 cells was determined using flow cytometry. Briefly, $2 \times 10^{5}$ cells were seeded in 6 well plates; 16 h post seeding, cells were treated with different concentrations of the compounds and incubated for 24 h , followed by flow cytometric analysis. Cells were collected by trypsinization, and washed once with phosphate buffered saline (PBS). Cells were then resuspended in propidium iodide staining buffer (1\% sodium citrate and $0.1 \%$ Triton X-100, supplemented with $50 \mu \mathrm{~g} / \mathrm{mL}$ propidium iodide and $25 \mu \mathrm{~g} / \mathrm{mL}$ RNase A). Cells were incubated in staining buffer for 30 minutes, followed by analysis on a CyFlow Space (Sysmex-Partec) flow cytometer.

Sub-G1 assay. Induction of apoptosis by different compounds was evaluated using Sub-G1 analysis. Briefly, $2 \times 10^{5}$ cells were seeded in 6 well plates. Cells were allowed to attach for 16 hours, followed by treatment with different concentrations of the compounds. Cells were incubated for 48 h , followed by sample processing using the process described above for cell cycle analysis.

Annexin V/Propidium Iodide Dual Staining. Induction of early and late apoptotic populations and necrosis was assayed employing Annexin V/Propidium dual staining assay. Briefly, $1.5 \times 10^{5}$ MCF-7 cells were seeded per well in 6-well plates, followed by incubation for 16 hours. Cells were then treated with $\mathrm{IC}_{50}$ concentrations of relevant compounds for 24 hours, followed by Annexin V/PI dual staining using Annexin V/PI apoptosis detection kit according to manufacturer's protocol. Staining was followed by analysis on a CyFlow Space (Sysmex-Partec) flow cytometer. Flow cytometric data was analyzed using FlowJo software.

Immunofluorescence staining. Induction of DNA damage was assessed using visualization of $\gamma$-H2AX foci by means of immunofluorescence staining and confocal microscopy. Briefly, $2 \times 10^{5}$ cells were seeded in 6 well plates on glass coverslips, followed by incubation for 16 hours to facilitate cellular attachment. Post incubation, cells were treated with $2.5 \mu \mathrm{M}$ of each compound for 24 hours, followed by immunofluorescence staining. Cells were fixed in a 3.5 \% paraformaldehyde solution, followed by permeabilization using PBS supplemented with 0.1 \% Triton X-100. Permeabilized cells were blocked for 2 h using a $5 \%$ BSA prepared in PBS supplement with $0.1 \%$ Tween 20. Cells were then treated with primary antibody (1:1000 dilution in PBS containing $0.1 \%$ Tween 20 and $2.5 \%$ BSA) for 16 h at $4^{\circ} \mathrm{C}$. Samples were then treated with AlexaFluor 488 tagged secondary antibody (1:2500 dilution in PBS containing $0.1 \%$ Tween 20 and $2.5 \%$ BSA) for 3 hours. Cells were washed thrice with PBS containing $0.1 \%$ Tween 20 , followed by drying and mounting on glass slides using a solution of $10 \mu \mathrm{~g} / \mathrm{mL}$ Hoechst 33258 in $80 \%$ glycerol. Samples were then visualized under a Zeiss

LSM 780 confocal microscope. For quantification of $\gamma$-H2AX foci, a minimum of 10 random fields were captured and number of cells containing $\gamma$ - H 2 AX foci were calculated as a percentage of total number of cells in each field.

## Cellular uptake

Cellular uptake of test compounds was estimated using GFAAS-based estimation of platinum concentration in cells treated with the test compounds. Briefly, $5 \times 10^{6}$ cells were seeded in 150 mm dishes, and cells were allowed to attach for 16 hours. Cells were then treated with $10 \mu \mathrm{M}$ concentration of each compound for 8 hours. Cells were then harvested, and $10 \%$ of cells were removed for protein estimation. The remaining cell pellet was extracted with $500 \mu \mathrm{~L}$ of concentrated nitric acid for 1 hour on ice. The extract was then centrifuged at 4000 rpm for 10 minutes at $4{ }^{\circ} \mathrm{C}$ to remove cellular debris. The supernatant was collected and subjected to GFAAS. Protein estimation was performed using the Bradford assay. The total protein in the entire cell pellet was back calculated, and the platinum concentration obtained through GFAAS was normalized with the total protein yield of each sample.

Table S1 Crystallographic and structure refinement data for $\left[\mathrm{Pt}(\mathrm{dppf})(4-\mathrm{Spy})_{2}\right] \cdot \mathrm{CHCl}_{3}$ $\left(\mathbf{1} \cdot \mathrm{CHCl}_{3}\right)$ and $\left[\mathrm{Pt}(\mathrm{dppf})(4 \text {-Sepy })_{2}\right] \cdot 2 \mathrm{CH}_{2} \mathrm{Cl}_{2}\left(\mathbf{2} \cdot 2 \mathrm{CH}_{2} \mathrm{Cl}_{2}\right)$

| Compounds | $1 \cdot \mathrm{CHCl}_{3}$ | 2. $2 \mathrm{CH}_{2} \mathrm{Cl}_{2}$ |
| :---: | :---: | :---: |
| Chemical Formula | $\mathrm{C}_{45} \mathrm{H}_{37} \mathrm{Cl}_{3} \mathrm{FeN}_{2} \mathrm{P}_{2} \mathrm{PtS}_{2}$ | $\mathrm{C}_{46} \mathrm{H}_{40} \mathrm{Cl}_{4} \mathrm{FeN}_{2} \mathrm{P}_{2} \mathrm{PtSe}{ }_{2}$ |
| Formula weight | 1089.11 | 1233.40 |
| Crystal Size (mm ${ }^{3}$ ) | $0.30 \times 0.30 \times 0.15$ | $0.30 \times 0.30 \times 0.02$ |
| T/K | 298(2) | 100(2) |
| $\lambda / \AA$ | $\operatorname{MoK} \alpha(\lambda=0.71073 \AA)$ | $\operatorname{MoK} \alpha(\lambda=0.71073 \AA)$ |
| Crystal system | Triclinic | Monoclinic |
| Space group | $P^{\overline{1}}$ | P 21/c |
| $\mathrm{a} / \AA$ | 9.91430(10) | 23.7129(7) |
| b/ $\AA$ | 12.5170(2) | 10.2790(2) |
| $\mathrm{c} / \AA$ | 18.0875(5) | 19.4397(5) |
| $\alpha /{ }^{\circ}$ | 83.9050(10) | 90 |
| $\beta /{ }^{\circ}$ | 76.9550(10) | 112.458(3) |
| $\gamma^{\prime 0}$ | 80.5420(10) | 90 |
| $\mathrm{V} / \AA^{3}$ | 2151.38(6) | 4379.0(2) |
| $\rho_{\text {calc }} / \mathrm{g} \mathrm{cm}^{-3}$ | 1.681 | 1.871 |
| Z | 2 | 4 |
| $\mu / \mathrm{mm}^{-1}$ | 3.978 | 5.539 |
| Reflection collected/ unique | 41553/10798 | 49730/11291 |
| Data/restraints/parameters | 10798 / 48/469 | 11291/67/ 542 |
| Final $\mathrm{R}_{1}, w \mathrm{R}_{2}$ indices | $\mathrm{R} 1=0.0258, \mathrm{wR} 2=0.0557$ | $\mathrm{R} 1=0.0289, \mathrm{wR} 2=0.0630$ |
| $\mathrm{R}_{1}, w \mathrm{R}_{2}$ (all data) | $\mathrm{R} 1=0.0334, \mathrm{wR} 2=0.0572$ | $\mathrm{R} 1=0.0404, \mathrm{wR} 2=0.0660$ |
| Largest diff. peak \& hole [e $\left.\AA^{-3}\right]$ | 1.109 and -0.788 | 1.326 and -1.180 |

Table S2 Crystallographic and structure refinement data for $[\mathrm{Pt}(\mathrm{dppf})(\mathrm{Sepy})]_{2}\left(\mathrm{O}_{3} \mathrm{SCF}_{3}\right)_{2} \cdot \mathrm{CH}_{2} \mathrm{Cl}_{2}\left(9 \mathrm{D} \cdot \mathrm{CH}_{2} \mathrm{Cl}_{2}\right)$ and $[\mathrm{Pt}(\mathrm{dppe})(4-\mathrm{Sepy})]_{2}\left(\mathrm{BPh}_{4}\right)_{2} \cdot 4 \mathrm{CH}_{2} \mathrm{Cl}_{2}$ (12D• $4 \mathrm{CH}_{2} \mathrm{Cl}_{2}$ ).

| Compounds | 9D $\cdot \mathrm{CH}_{2} \mathrm{Cl}_{2}$ | 12D $\cdot 4 \mathrm{CH}_{2} \mathrm{Cl}_{2}$ |
| :---: | :---: | :---: |
| Chemical Formula | $\mathrm{C}_{81} \mathrm{H}_{66} \mathrm{Cl}_{2} \mathrm{~F}_{6} \mathrm{Fe}_{2} \mathrm{~N}_{2} \mathrm{O}_{6} \mathrm{P}_{4} \mathrm{Pt}_{2} \mathrm{~S}_{2} \mathrm{Se}_{2}$ | $\mathrm{C}_{114} \mathrm{H}_{104} \mathrm{~B}_{2} \mathrm{Cl}_{8} \mathrm{~N}_{2} \mathrm{P}_{4} \mathrm{Pt}_{2} \mathrm{Se}_{2}$ |
| Formula weight | 2196.05 | 2479.19 |
| Crystal Size ( $\mathrm{mm}^{3}$ ) | $0.50 \times 0.50 \times 0.10$ | $0.16 \times 0.14 \times 0.06$ |
| T/K | 298(2) | 150.15 |
| $\lambda / \AA$ | $\mathrm{CuK} \alpha(\lambda=1.54184 \AA)$ | $\operatorname{MoK} \alpha(\lambda=0.71073 \AA)$ |
| Crystal system | Monoclinic | triclinic |
| Space group | P 21/c | $P^{\overline{1}}$ |
| a/ $\AA$ | 12.8799(2) | 11.5598(19) |
| $\mathrm{b} / \AA$ | 16.5012(3) | 15.143(2) |
| c/Å | 38.1414(5) | 15.801(3) |
| $\alpha /{ }^{\circ}$ | 90 | 86.121(2) |
| $\beta /{ }^{\circ}$ | 98.2750(10) | 72.408(2) |
| $\gamma /{ }^{\circ}$ | 90 | 84.689(2) |
| $\mathrm{V} / \AA^{3}$ | 8021.9(2) | 2622.9(7) |
| $\rho_{\text {calc }} / \mathrm{g} \mathrm{cm}^{-3}$ | 1.818 | 1.570 |
| Z | 4 | 1 |
| $\mu / \mathrm{mm}^{-1}$ | 12.676 | 3.672 |
| Reflection collected/ unique | 129978/15811 | 48295/11872 |
| Data/restraints/parameters | 15811/392/ 1084 | 11872/7/602 |
| Final $\mathrm{R}_{1}, w \mathrm{R}_{2}$ indices | $\mathrm{R} 1=0.0412, \mathrm{wR} 2=0.0932$ | $\mathrm{R}_{1}=0.0366, \mathrm{wR}_{2}=0.0753$ |
| $\mathrm{R}_{1}, w \mathrm{R}_{2}$ (all data) | $\mathrm{R} 1=0.0601, \mathrm{wR} 2=0.1019$ | $\mathrm{R}_{1}=0.0503, \mathrm{wR}_{2}=0.0826$ |
| Largest diff. peak \& hole [ $\mathrm{E}^{-3}{ }^{\text {] }}$ ] | 0.92 and -1.31 | 2.091 and -2.668 |

Table S3 Crystallographic and structure refinement data for $[\operatorname{Pt}(\mathrm{dppf})(\mathrm{Spy})]_{4}\left(\mathrm{O}_{3} \mathrm{SCF}_{3}\right)_{4}$ $\left(7 \mathrm{~T} \cdot 3 \mathrm{CHCl}_{3} \cdot 2 \mathrm{CF}_{3} \mathrm{SO}_{3} \mathrm{H}\right) \quad$ and $\quad[\mathrm{Pt}(\mathrm{dppf})(\mathrm{Sepy})]_{4}\left(\mathrm{O}_{3} \mathrm{SCF}_{3}\right)_{4} \cdot 5 \mathrm{CHCl}_{3} \cdot 2 \mathrm{CF}_{3} \mathrm{SO}_{3} \mathrm{H}$ $\left(9 \mathrm{~T} \cdot 5 \mathrm{CHCl}_{3} \cdot 2 \mathrm{CF}_{3} \mathrm{SO}_{3} \mathrm{H}\right)$.

| Compounds | $7 \mathrm{~T} \cdot 3 \mathrm{CHCl}_{3} \cdot 2 \mathrm{CF}_{3} \mathrm{SO}_{3} \mathrm{H}$ | 9T-5 $\mathrm{CHCl}_{3} \cdot 2 \mathrm{CF}_{3} \mathrm{SO}_{3} \mathrm{H}$ |
| :---: | :---: | :---: |
| Chemical Formula | $\mathrm{C}_{165} \mathrm{H}_{133} \mathrm{Cl}_{9} \mathrm{~F}_{18} \mathrm{Fe}_{4} \mathrm{~N}_{4} \mathrm{O}_{18} \mathrm{P}_{8} \mathrm{Pt}_{4} \mathrm{~S}_{10}$ | $\mathrm{C}_{167} \mathrm{H}_{135} \mathrm{Cl}_{15} \mathrm{~F}_{18} \mathrm{Fe}_{4} \mathrm{~N}_{4} \mathrm{O}_{18} \mathrm{P}_{8} \mathrm{Pt}_{4} \mathrm{~S}_{6} \mathrm{Se}_{4}$ |
| Formula weight | 4692.92 | 5119.25 |
| Crystal Size (mm ${ }^{3}$ ) | $0.20 \times 0.20 \times 0.10$ | $0.30 \times 0.20 \times 0.10$ |
| T/K | 298(2) | 298(2) |
| $\lambda \AA$ | $\operatorname{CuK} \alpha(\lambda=1.54184 \AA)$ | $\operatorname{MoK} \alpha(\lambda=0.71073 \AA)$ |
| Crystal system | Tetragonal | Tetragonal |
| Space group | I $4_{1} / \mathrm{a}$ | $I 4_{l} /$ a |
| $\mathrm{a} / \AA$ | 19.9324(4) | 20.2575(3) |
| b/Å | 19.9324(4) | 20.2575(3) |
| c/ $\AA$ | 47.0921(19) | 47.4559(10) |
| $\alpha /{ }^{\circ}$ | 90 | 90 |
| $\beta /{ }^{\circ}$ | 90 | 90 |
| $\gamma^{\prime 0}$ | 90 | 90 |
| $\mathrm{V} / \AA^{3}$ | 18709.7(11) | 19474.3(7) |
| $\rho_{\text {calc }} / \mathrm{g} \mathrm{cm}^{-3}$ | 1.666 | 1.746 |
| Z | 4 | 4 |
| $\mu / \mathrm{mm}^{-1}$ | 11.385 | 4.310 |
| Reflection collected/ unique | 33113/9333 | 45274/12125 |
| Data/restraints/parameters | 9333/ 61 / 479 | 12125/76/527 |
| Final $\mathrm{R}_{1}, w \mathrm{R}_{2}$ indices | $\mathrm{R} 1=0.0520, \mathrm{wR} 2=0.1426$ | $\mathrm{R} 1=0.0328, \mathrm{wR} 2=0.0849$ |
| $\mathrm{R}_{1}, w \mathrm{R}_{2}$ (all data) | $\mathrm{R} 1=0.0696, \mathrm{wR} 2=0.1570$ | $\mathrm{R} 1=0.0510, \mathrm{wR} 2=0.0937$ |
| Largest diff. peak \& hole $\left[e^{-3}\right]$ | 1.584 and -0.995 | 0.952 and -0.553 |

Table S4 Calculated and experimental peaks of the fragmented ions of $[\mathrm{Pt}(\mathrm{dppf})(4-$ Spy) $]_{n}(\mathrm{OTf})_{\mathrm{n}}(7)$.

| $m / z$ | Ion | Calculated <br> peak of the <br> most <br> abundant ion | Experimental <br> peak of the <br> most <br> abundant ion |
| :--- | :--- | :--- | :--- |
| 2875.12 | $\left(\left[\mathrm{M}_{3}-\mathrm{OTf}\right]^{+}, 19 \%\right)$ | 2876.12 | 2876.12 |
| $4295.36 / 2=2147.68$ | $\left(\left[\mathrm{M}_{5}-5 \mathrm{OTf}\right]^{2+}, 2 \%\right)$ | 2148.68 | 2148.64 |
| $4231.33 / 2=2116.66$ | $\left(\left[\mathrm{M}_{5}-\left(5 \mathrm{OTf}+\mathrm{C}_{5} \mathrm{H}_{4}\right)\right]^{2+}, 2 \%\right)$ | 2116.65 | 2116.65 |
| 1867.10 | $\left(\left[\mathrm{M}_{2}-\mathrm{OTf}\right]^{+}, 53 \%\right)$ | 1868.10 | 1868.09 |
| $3586.25 / 2=1793.13$ | $\left(\left[\mathrm{M}_{4}+\mathrm{H}-3 \mathrm{OTf}\right]^{2+}, 7 \%\right)$ | 1794.12 | 1794.10 |
| 1738.97 | $\left(\left[\mathrm{M}_{3}+2 \mathrm{CH} \mathrm{H}_{3} \mathrm{CN}-(2 \mathrm{dppf}+\mathrm{Spy}+\right.\right.$ | 1739.96 | 1739.99 |
| 1718.15 | ${\left.\mathrm{OTf})]^{+}, 17 \%\right)}^{\left(\left[\mathrm{M}_{2}-2 \mathrm{OTf}\right]^{+}, 15 \%\right)}$ <br> 1641.11 | $\left(\left[\mathrm{M}_{2}-(2 \mathrm{OTf}+\mathrm{Ph})\right]^{+}, 46 \%\right)$ | 1719.15 |

Table S5 Calculated and experimental peaks of the fragmented ions of $[\operatorname{Pt}(\operatorname{dppf})(4-$ Sepy) $]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(9)$.

| $m / z$ | Ion | Calculated peak of the most abundant ion | Experimental peak of the most abundant ion |
| :---: | :---: | :---: | :---: |
| 2665.40/2 $=1332.70$ | $\left(\left[\mathrm{M}_{4}+\mathrm{H}-(\mathrm{dppf}+\mathrm{Sepy}+11 \mathrm{Ph})\right]^{2+}\right.$, | 1331.71 | 1331.53 |
|  | 2\%) |  |  |
| $2669.83 / 2=1334.91$ | $\left(\left[\mathrm{M}_{4}+\mathrm{H}-(2 \mathrm{dppf}+3 \mathrm{OTf})\right]^{2+}, 2 \%\right)$ | 1333.92 | 1334.08 |
| $2894.70 / 2=1447.35$ | $\left(\left[\mathrm{M}_{4}+2 \mathrm{CH}_{3} \mathrm{CN}-(2 \mathrm{dppf}+\mathrm{OTf}+\right.\right.$ | 1446.35 | 1446.16 |
|  | 2Ph) ${ }^{2+}$, 4\%) |  |  |
| $2900.39 / 2=1450.19$ | $\left(\left[\mathrm{M}_{4}+\mathrm{H}-(\mathrm{dppf}+10 \mathrm{Ph})\right]^{2+}, 9 \%\right)$ | 1449.20 | 1449.14 |
| 1625.08 | $\left(\left[\mathrm{M}_{2}+3 \mathrm{CH}_{3} \mathrm{CN}-(2 \mathrm{OTf}+\right.\right.$ Sepy + | 1625.09 | 1625.15 |
|  | 2Ph) $\left.{ }^{+}, 23 \%\right)$ |  |  |
| 1666.99 | $\left(\left[\mathrm{M}_{2}+2 \mathrm{CH}_{3} \mathrm{CN}+2 \mathrm{H}-(2 \mathrm{OTf}+\right.\right.$ | 1666.00 | 1666.08 |
|  | 3Ph) $\left.{ }^{+}, 26 \%\right)$ |  |  |
| 1688.11 | $\left(\left[\mathrm{M}_{2}+\mathrm{CH}_{3} \mathrm{OH}-(2 \mathrm{OTf}+\mathrm{Sepy})\right]^{+}\right.$, | 1688.11 | 1688.08 |
|  | 100\%) |  |  |
| 1736.00 | $\left(\left[\mathrm{M}_{2}-(2 \mathrm{OTf}+\mathrm{py})\right]^{+}, 75 \%\right)$ | 1735.01 | 1735.11 |

Table S6 Calculated and experimental peaks of the fragmented ions of $\left[\mathrm{Pt}_{( }\left(\mathrm{PEt}_{3}\right)_{2}(4-\right.$ Sepy) $]_{n}(O T f)_{n}(\mathbf{1 0})$.

| $m / z$ | Ion | Calculated peak of the most abundant ion | Experimental peak of the most abundant ion |
| :---: | :---: | :---: | :---: |
| 1944.04 | $\left(\left[\mathrm{M}_{4}-\left(4 \mathrm{OTf}+3 \mathrm{PEt}_{3}+2 \mathrm{Et}\right)\right]^{+}, 2 \%\right)$ | 1941.04 | 1940.94 |
| 1866.01 | $\left(\left[\mathrm{M}_{4}-\left(4 \mathrm{OTf}+3 \mathrm{PEt}_{3}+\mathrm{py}+2 \mathrm{Et}\right)\right]^{+}, 2 \%\right)$ | 1863.01 | 1863.01 |
| 1713.98 | $\left(\left[\mathrm{M}_{4}+\mathrm{H}-\left(3 \mathrm{OTf}+\mathrm{Pt}\left(\mathrm{PEt}_{3}\right)_{2}+\mathrm{Sepy}+7 \mathrm{Et}\right)\right]^{+}, 2 \%\right)$ | 1711.98 | 1712.05 |
| 1595.07 | $\left(\left[\mathrm{M}_{4}+2 \mathrm{H}-\left(4 \mathrm{OTf}+\mathrm{Pt}\left(\mathrm{PEt}_{3}\right)_{2}+\text { Sepy }+6 \mathrm{Et}\right)\right]^{+}\right.$, | 1593.08 | 1593.04 |
|  | 12\%) |  |  |
| 1381.17 | $\left(\left[\mathrm{M}_{2}+2 \mathrm{CH}_{3} \mathrm{CN}+\mathrm{H}-(\mathrm{OTf}+\mathrm{Et})\right]^{+}, 100 \%\right)$ | 1381.17 | 1381.16 |
| 1327.15 | ( $\left.\left[\mathrm{M}_{2}-\mathrm{OTf}\right]^{+}, 33 \%\right)$ | 1326.15 | 1326.14 |
| 1311.08 | $\left(\left[\mathrm{M}_{2}+2 \mathrm{H}-(\mathrm{Se}+3 \mathrm{Et})\right]^{+}, 74 \%\right)$ | 1311.08 | 1311.13 |
| 1231.21 | $\left(\left[\mathrm{M}_{2}+2 \mathrm{CH}_{3} \mathrm{CN}-(2 \mathrm{OTf}+\mathrm{Et})\right]^{+}, 36 \%\right)$ | 1230.21 | 1230.20 |
| 1216.00 | $\left(\left[\mathrm{M}_{2}+\mathrm{CH}_{3} \mathrm{CN}+2 \mathrm{H}-(5 \mathrm{Et}+\text { Sepy })\right]^{+}, 14 \%\right)$ | 1216.00 | 1216.06 |
| 1204.19 | $\left(\left[\mathrm{M}_{2}+2 \mathrm{CH}_{3} \mathrm{CN}+2 \mathrm{H}-(2 \mathrm{OTf}+2 \mathrm{Et})\right]^{+}, 35 \%\right)$ | 1202.19 | 1202.19 |



Fig. S1 ${ }^{1} \mathrm{H}$ NMR spectra $\left(300 \mathrm{MHz}, \mathrm{CDCl}_{3}\right)$ of $\left[\mathrm{Pt}(\mathrm{dppf})(4-\mathrm{Spy})_{2}\right](\mathbf{1})$.




Fig. S2 ${ }^{31} \mathrm{P}\left\{{ }^{1} \mathrm{H}\right\}$ NMR spectra $\left.121.5 \mathrm{MHz}, \mathrm{CDCl}_{3}\right)$ of $\left[\mathrm{Pt}(\mathrm{dppf})(4-\mathrm{Spy})_{2}\right](\mathbf{1})$.


Fig. S3 ${ }^{195} \mathrm{Pt}\left\{{ }^{1} \mathrm{H}\right\}$ NMR spectra $\left.64.5 \mathrm{MHz}, \mathrm{CDCl}_{3}\right)$ of $\left[\mathrm{Pt}(\mathrm{dppf})(4-\mathrm{Spy})_{2}\right](\mathbf{1})$.


Fig. S4 ${ }^{1} \mathrm{H}$ NMR spectra $\left(600 \mathrm{MHz}, \mathrm{CDCl}_{3}\right)$ of $\left[\mathrm{Pt}(\mathrm{dppf})(4-\mathrm{Sepy})_{2}\right](\mathbf{2})$.


Fig. S5 ${ }^{31} \mathrm{P}\left\{{ }^{1} \mathrm{H}\right\}$ NMR spectra ( $243 \mathrm{MHz}, \mathrm{CDCl}_{3}$ ) of $\left[\mathrm{Pt}(\mathrm{dppf})(4-\mathrm{Sepy})_{2}\right](\mathbf{2})$.


Fig. S6 ${ }^{31} \mathrm{P}\left\{{ }^{1} \mathrm{H}\right\}$ NMR spectra $\left.162 \mathrm{MHz}, \mathrm{CD}_{2} \mathrm{Cl}_{2}\right)$ of $[\mathrm{Pt}(\text { dppe })(4-\mathrm{Sepy})]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(6)$.


Fig. S7 ${ }^{195} \mathrm{Pt}\left\{{ }^{1} \mathrm{H}\right\}$ NMR $\left(85.6 \mathrm{MHz}, \mathrm{CD}_{2} \mathrm{Cl}_{2}\right)$ spectra of $[\mathrm{Pt}(\mathrm{dppe})(4-\mathrm{Sepy})]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(\mathbf{6})$


Fig. S8 ${ }^{1} \mathrm{H}$ NMR $\operatorname{spectra}\left(400 \mathrm{MHz}, \mathrm{CD}_{2} \mathrm{Cl}_{2}\right)$ of $[\mathrm{Pt}(\text { dppe })(4-\mathrm{Sepy})]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(\mathbf{6})$


Fig. S9 ${ }^{1} \mathrm{H}$ NMR spectra $\left(300 \mathrm{MHz}, \mathrm{CD}_{2} \mathrm{Cl}_{2}\right)$ of $[\mathrm{Pt}(\mathrm{dppf})(4-\mathrm{Spy})]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(7)$ obtained from reaction between $\left[\mathrm{Pt}(\mathrm{dppf})(4-\mathrm{Spy})_{2}\right](\mathbf{1})$ and $\operatorname{Pt}(\mathrm{dppf})(\mathrm{OTf})_{2}$ in 1:1 stoichiometry.



Fig. S10 ${ }^{31} \mathrm{P}\left\{{ }^{1} \mathrm{H}\right\}$ NMR spectra $\left(121.5 \mathrm{MHz}, \mathrm{CD}_{2} \mathrm{Cl}_{2}\right)$ of $[\mathrm{Pt}(\mathrm{dppf})(4-\mathrm{Spy})]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(7)$ obtained from reaction between $\left[\operatorname{Pt}(\mathrm{dppf})(4-\mathrm{Spy})_{2}\right](\mathbf{1})$ and $\mathrm{Pt}(\mathrm{dppf})(\mathrm{OTf})_{2}$ in 1:1 stoichiometry.


Fig. S11 ${ }^{1} \mathrm{H}$ NMR spectra ( $300 \mathrm{MHz}, \mathrm{CD}_{2} \mathrm{Cl}_{2}$ ) of $[\mathrm{Pt}(\mathrm{dppf})(4-\mathrm{Spy})]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(7)$ obtained from reaction between $\mathrm{Na}(4-\mathrm{Spy})$ and $\mathrm{Pt}(\mathrm{dppf})(\mathrm{OTf})_{2}$ in $1: 1$ stoichiometry.


Fig. S12 ${ }^{31} \mathrm{P}\left\{{ }^{1} \mathrm{H}\right\}$ NMR spectra $\left(121.5 \mathrm{MHz}, \mathrm{CD}_{2} \mathrm{Cl}_{2}\right)$ of $[\mathrm{Pt}(\mathrm{dppf})(4-\mathrm{Spy})]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(7)$ obtained from reaction between $\mathrm{Na}(4-\mathrm{Spy})$ and $\operatorname{Pt}(\mathrm{dppf})(\mathrm{OTf})_{2}$ in $1: 1$ stoichiometry.


Fig. S13 (A) ${ }^{31} \mathrm{P}\left\{{ }^{1} \mathrm{H}\right\}$ NMR spectrum ( 121.5 MHz ); (B) Ferrocenyl region of the ${ }^{1} \mathrm{H}$ NMR spectrum $(300 \mathrm{MHz})$ of $[\mathrm{Pt}(\mathrm{dppf})(4-\mathrm{Spy})]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(7)$ in $\mathrm{CD}_{2} \mathrm{Cl}_{2}(\mathbf{D}=\operatorname{dimer} 7 \mathbf{D}, \mathbf{T}=$ tetramer 7T, $\mathbf{O}_{\mathbf{1}}=$ oligomer 1, $\mathbf{O}_{\mathbf{2}}=$ oligomer 2) obtained from reaction between $\left[\operatorname{Pt}(\mathrm{dppf})(4-\mathrm{Spy})_{2}\right](\mathbf{1})$ and $\operatorname{Pt}(\mathrm{dppf})(\mathrm{OTf})_{2}$ in 1:1 stoichiometry in NMR tube after 5 days.


Fig. S14 ${ }^{31} \mathrm{P}\left\{{ }^{1} \mathrm{H}\right\}$ NMR (121.5 MHZ, $\mathrm{CD}_{2} \mathrm{Cl}_{2}$ ) spectra of (A) [Ptdppf(4-Spy) ${ }_{2}$ ] (1), (B) $\left[\operatorname{Ptdppf}(4-\operatorname{Spy})_{2}\right](\mathbf{1})+\left[\operatorname{Ptdppf}(\mathrm{OTf})_{2}\right]$ immediately, After (C) 2 h , (D) 6 h , (E) 24 h , (F) 30 h , (G) 48 h , (H) 54 h , (I) 5 days, (J) 6 days.


$\begin{array}{lllllllllllllll}8.20 & 8.10 & 8.00 & 7.90 & 7.80 & 7.70 & 7.60 & 7.50 & 7.40 & 7.30 & 7.20 & 7.10 & 7.00 & 6.90 & 6.80\end{array}$


Fig. $\mathbf{S 1 5}{ }^{1} \mathrm{H}$ NMR spectra $\left(300 \mathrm{MHz}, \mathrm{CD}_{2} \mathrm{Cl}_{2}\right)$ of $[\operatorname{Pt}(\mathrm{dppf})(4-\mathrm{Sepy})]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(\mathbf{9})$.


Fig. S16 ${ }^{31} \mathrm{P}\left\{{ }^{1} \mathrm{H}\right\}$ NMR spectra $\left.121.5 \mathrm{MHz}, \mathrm{CD}_{2} \mathrm{Cl}_{2}\right)$ of $[\operatorname{Pt}(\mathrm{dppf})(4-\mathrm{Sepy})]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(9)$.


Fig. S17 (A) ${ }^{31} \mathrm{P}\left\{{ }^{1} \mathrm{H}\right\}$ NMR spectrum (121.5 MHz); (B) Ferrocenyl region of the ${ }^{1} \mathrm{H}$ NMR spectrum ( 300 MHz ) of $\left[\mathrm{Pt}(\mathrm{dppf})\left(4-\mathrm{SeC}_{5} \mathrm{H}_{4} \mathrm{~N}\right)\right]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(\mathbf{9})$ in $\mathrm{CD}_{2} \mathrm{Cl}_{2}(\mathbf{D}=\operatorname{dimer} \mathbf{9 D}, \mathbf{T}=$ tetramer 9T, $\mathbf{B}=$ bridging).


Fig. S18 ${ }^{1} \mathrm{H}$ NMR $\operatorname{spectra}\left(300 \mathrm{MHz}, \mathrm{CD}_{2} \mathrm{Cl}_{2}\right)$ of $\left[\mathrm{Pt}\left(\mathrm{PEt}_{3}\right)_{2}(4-\mathrm{Sepy})\right]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(\mathbf{1 0})$.


Fig. S19 ${ }^{31} \mathrm{P}\left\{{ }^{1} \mathrm{H}\right\}$ NMR spectra $\left.121.5 \mathrm{MHz}, \mathrm{CD}_{2} \mathrm{Cl}_{2}\right)$ of $\left[\mathrm{Pt}^{( }\left(\mathrm{PEt}_{3}\right)_{2}(4-\mathrm{Sepy})\right]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(\mathbf{1 0})$.




Fig. S20 ${ }^{77} \mathrm{Se}\left\{{ }^{1} \mathrm{H}\right\}$ NMR spectra $\left.57.2 \mathrm{MHz}, \mathrm{CD}_{2} \mathrm{Cl}_{2}\right)$ of $\left[\mathrm{Pt}\left(\mathrm{PEt}_{3}\right)_{2}(4-\mathrm{Sepy})\right]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(\mathbf{1 0})$.


Fig. S21 ${ }^{195} \mathrm{Pt}\left\{{ }^{1} \mathrm{H}\right\}$ NMR spectra $\left.64.5 \mathrm{MHz}, \mathrm{CD}_{2} \mathrm{Cl}_{2}\right)$ of $\left[\mathrm{Pt}_{( }\left(\mathrm{PEt}_{3}\right)_{2}(4-\mathrm{Sepy})\right]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(\mathbf{1 0})$.




Fig. S23 ${ }^{31} \mathrm{P}\left\{{ }^{1} \mathrm{H}\right\}$ NMR spectra $\left.121.5 \mathrm{MHz}, \mathrm{dmso}^{-\mathrm{d}_{6}}\right)$ of $\left[\mathrm{Pt}^{( }\left(\mathrm{PEt}_{3}\right)_{2}(4-\mathrm{Sepy})\right]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(\mathbf{1 0})$.


Scheme S1 Structural drawing of $\left[\mathrm{Pt}_{2}\left(\mathrm{PEt}_{3}\right)_{4}\left(\mathrm{~S}\left(\mathrm{C}_{12} \mathrm{H}_{8}\right) \mathrm{S}\right)\right]_{2}(\mathrm{OTf})_{4}(\mathbf{1 1 )}$


Fig. S24 ORTEP diagram of $[\operatorname{Pt}(\mathrm{dppe})(4-\mathrm{Sepy})]_{2}\left(\mathrm{BPh}_{4}\right)_{2}(\mathbf{1 2 D})$ ellipsoids drawn at $50 \%$ probability. The hydrogen atoms, dppe phenyl groups, and $\mathrm{BPh}_{4}$ ions are omitted for clarity.


Fig. S25 ORTEP diagram of $\left[\operatorname{Pt}\left(\mathrm{PEt}_{3}\right)_{2}(4-\mathrm{Sepy})\right]_{2}\left(\mathrm{BPh}_{4}\right)_{2}(\mathbf{1 3 D})$ ellipsoids drawn at $50 \%$ probability. The $\mathrm{BPh}_{4}$ ions were masked. The hydrogen atoms are omitted for clarity.


Fig. S26 ESI-mass spectrum of $[\operatorname{Pt}(\mathrm{dppf})(4-\operatorname{Sepy})]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}$ (9). The insets show the experimentally obtained (below) isotope patterns of the fragments with those simulated (above) on the basis of natural isotope abundances. The found and calcd values are for the most abundant peak of ion.


Fig. S27 ESI-mass spectrum of $\left[\mathrm{Pt}_{\left.\left(\mathrm{PEt}_{3}\right)_{2}(4-\mathrm{Sepy})\right]_{n}(\mathrm{OTf})_{\mathrm{n}}(\mathbf{1 0}) \text {. The insets show the }}\right.$ experimentally obtained (below) isotope patterns of the fragments with those simulated (above) on the basis of natural isotope abundances. The found and calcd values are for the most abundant peak of ion.


Fig. S28 ORTEP diagram of $\left[\operatorname{Pt}(\mathrm{dppf})(4-\mathrm{Spy})_{2}\right](1)$ ellipsoids drawn at $35 \%$ probability. The hydrogen atoms are omitted for clarity.


Fig. 29 ORTEP diagram of $[\operatorname{Pt}(\mathrm{dppf})(4-\mathrm{Sepy})]_{4}(\mathrm{OTf})_{4}(9 T)$ ellipsoids drawn at $35 \%$ probability. The dppf phenyl groups, hydrogen atoms, and triflate ions are omitted for clarity.


Fig. S30 ${ }^{1} \mathrm{H}$ NMR spectra $(300 \mathrm{MHz})$ of A) mixture of cell culture medium and DMSO- $\mathrm{d}_{6}(1: 4$, $\mathrm{v} / \mathrm{v})$, B) with $4,4^{\prime}-\mathrm{py}_{2} \mathrm{Se}_{2}$ (free ligand), and with the $\left.\left[\mathrm{Pt}^{( }\left(\mathrm{PEt}_{3}\right)_{2}(4-\mathrm{Sepy})\right]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(\mathbf{1 0}), \mathrm{C}\right)$ immediately, after D) $6 \mathrm{~h}, \mathrm{E}) 1$ day and F) 3 days in the mixture of culture medium and DMSO$\mathrm{d}_{6}(1: 4, \mathrm{v} / \mathrm{v})$.


Fig. S31 UV-Vis spectra of $\left[\mathrm{Pt}_{\left.\left(\mathrm{PEt}_{3}\right)_{2}(4-\mathrm{Sepy})\right]_{\mathrm{n}}(\mathrm{OTf})_{\mathrm{n}}(\mathbf{1 0}) \text { in mixture of cell culture }}\right.$ medium and DMSO (1:4, v/v) overtime scale.


Fig. S32 Dose response curves of the different synthesized compounds against MCF7 cells determined by MTT assay. Cells were treated with $1,5,10$ or $25 \mu \mathrm{M}$ of each compound for 48 hours, followed by determination of cellular viability by MTT assay.



Fig. S33 Dose response curves of shortlisted compounds against MCF7 cells determined by clonogenic assay. Cells were incubated with 100,500 or 1000 nM of each compound for 14 days, followed by staining of colonies with crystal violet and quantification of the number of colonies containing $>30$ cells under a light microscope.


Fig. S34 Histograms representing Sub G1 analysis of MCF7 cells treated with the different compounds. Cells were treated with indicated concentrations of each compound for 48 hours, followed by Sub G1 analysis employing flow cytometry.


Fig. S35 Cell cycle analysis of MCF7 cells treated with indicated concentrations of the different compounds. Cells were treated with 1 or $5 \mu \mathrm{M}$ of each compound for 24 hours, followed by analysis of cell cycle distribution using flow cytometry.

